Sarepta Therapeutics, financials
$18.64−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $401.3M | $730.8M | $442.9M | $399.4M | $611.1M | $744.9M | $658.4M | $467.2M | $362.9M | $413.5M | $396.8M | $331.8M |
| Gross profit | $251.9M | $622.0M | $44.2M | $248.6M | $458.5M | $607.3M | $526.1M | $375.5M | $318.4M | $362.9M | $352.6M | $294.8M |
| Gross margin | 62.8% | 85.1% | 10.0% | 62.2% | 75.0% | 81.5% | 79.9% | 80.4% | 87.7% | 87.8% | 88.9% | 88.8% |
| Operating income | $13.3M | $358.4M | -$411.6M | -$103.4M | $115.6M | -$300.4M | $161.7M | $22.2M | -$701.0K | $34.9M | $24.6M | -$20.8M |
| Net income | -$4.9M | $331.0M | -$282.8M | -$179.9M | $196.9M | -$447.5M | $159.0M | $33.6M | $6.5M | $36.1M | $45.7M | -$40.9M |
| Net margin | −1.2% | 45.3% | −63.9% | −45.1% | 32.2% | −60.1% | 24.2% | 7.2% | 1.8% | 8.7% | 11.5% | −12.3% |
| Diluted EPS | $-0.05 | $2.88 | $-2.94 | $-1.80 | $1.89 | $-4.60 | $1.20 | $0.34 | $0.07 | $0.37 | $0.44 | $-0.46 |
| EBITDA | $62.7M | $369.0M | -$404.8M | -$44.4M | $126.4M | -$290.4M | $172.1M | $32.0M | $8.0M | $43.6M | $24.6M | -$9.9M |
| Operating cash flow | $197.1M | -$202.7M | $131.2M | -$14.6M | $261.3M | -$583.4M | $92.0M | -$70.7M | $14.9M | -$242.1M | -$54.7M | -$114.7M |
| Free cash flow | $196.5M | -$204.8M | $127.6M | -$37.5M | $229.5M | -$627.1M | $54.0M | -$108.0M | -$14.2M | -$274.5M | -$73.7M | -$144.4M |
| Diluted shares | 105.4M | 121.9M | 96.3M | 100.2M | 106.6M | 97.4M | 132.8M | 100.4M | 99.1M | 99.1M | 103.8M | 88.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $571.1M | $464.4M | $801.3M | $613.1M | $510.6M | $240.9M |
| Short-term investments | $217.3M | $188.7M | $138.4M | $237.9M | $289.5M | $281.9M |
| Total debt | $847.6M | $838.2M | $829.0M | $1.04B | $1.14B | $1.14B |
| Total assets | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B |
| Total liabilities | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B |
| Shareholders' equity | $1.53B | $1.51B | $1.14B | $1.32B | $1.36B | $1.14B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology